SCHEMBL4122902

SCHEMBL4122902

CCOC(=O)c1ccc(NC(=O)Nc2ccccc2Cl)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.65
MAPT P10636 10/20 0.63
MEN1 O00255 8/20 0.63
KMT2A Q03164 8/20 0.63
CASP3 P42574 2/20 0.63
SENP7 Q9BQF6 2/20 0.63
LMNA P02545 3/20 0.60
NPSR1 Q6W5P4 2/20 0.60
RAB9A P51151 9/20 0.60
NPC1 O15118 8/20 0.60
TDP1 Q9NUW8 2/20 0.60
NAMPT P43490 1/20 0.60
SMN1; SMN2 Q16637 6/20 0.59
GAA P10253 4/20 0.59
MAPK1 P28482 2/20 0.59
POLB P06746 2/20 0.58
SENP8 Q96LD8 1/20 0.58
SENP6 Q9GZR1 1/20 0.58
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1019967 0.84 SMN1; SMN2 (0.78) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL4915540 0.84 NPC1 (0.76) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL4105986 0.84 RAB9A (0.64) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL4111911 0.83 TRPV1 (0.75) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL14825275 0.83 MAPT (0.69) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL4915756 0.83 MAPT (0.72) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL5157218 0.82 NPC1 (0.59) MAPTMEN1KMT2ACASP3SENP7
SCHEMBL11847456 0.81 MAPT (0.72) MAPTMEN1KMT2ACASP3SENP7
SCHEMBL5074250 0.81 MEN1 (0.65) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL11007737 0.81 MEN1 (0.61) TRPV1MAPTMEN1KMT2ACASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP claimed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 TRPV1 169/4885MAPT 1654/4885MEN1 3273/4885
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R TRPV1 446/4885MAPT 4151/4885MEN1 4843/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R TRPV1 446/4885MAPT 4151/4885MEN1 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.